Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
77.71
+1.72 (+2.26%)
4:48:19 PM EDT: $77.58 -0.13 (-0.17%)
Earnings Announcements

BRENZYS® (Etanercept Injection) Now Indicated For The Treatment Of Plaque Psoriasis, Psoriatic Arthritis And Juvenile Idiopathic Arthritis

Published: 09/15/2020 11:07 GMT
Merck & Co Inc (MRK) - Brenzys® (etanercept Injection) Now Indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis.
Merck & Co Inc - Health Canada Has Approved Brenzys , a Tnf-inhibitor, for Four New Indications.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.